AVROBIO Inc (AVRO) Stock
AVRO is no longer traded. AVROBIO was delisted from the Nasdaq in June 2024.
Prices on this page are historical; the last trade was June 20, 2024 at $1.40.
AVROBIO stock price history
AVRO final trading statistics
- Final close
- $1.40
- Final trading day
- Jun 20, 2024
- Market cap at delisting
- $5.24M
- Shares outstanding
- 3.74M
- Final 52-week range
- $1.17 – $1.53
- Avg. volume (final 3 mo.)
- 263,680
- All-time high (split-adj.)
- $59250.00 · Dec 2016
- All-time low (split-adj.)
- $1.19 · Apr 2024
- Return since IPO
- -99.9%
- Beta
- 1.22
- Book value / share
- $23.75
- Price / book
- 0.06
AVROBIO annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $0.00 | $12.2M | -$1.58 |
| FY2022 | $0.00 | -$106.0M | -$2.41 |
| FY2021 | $0.00 | -$117.7M | -$2.79 |
| FY2020 | $0.00 | -$118.5M | -$3.31 |
| FY2019 | $0.00 | -$72.1M | -$2.68 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About AVROBIO Inc
AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
AVROBIO stock FAQ
What happened to AVROBIO stock?
AVROBIO stock was delisted from the Nasdaq. Its final close was $1.40 on June 20, 2024.
Is AVRO stock still trading?
No. AVRO was delisted from the Nasdaq in June 2024 and no longer trades on a U.S. exchange.
What was the last price of AVRO stock?
AVRO closed at $1.40 on its final trading day, June 20, 2024, for a market value of about $5.24M.
What were AVROBIO's revenue and earnings in its last full fiscal year?
AVROBIO reported revenue of $0.00 and net income of $12.2M in fiscal 2023, its last full year as a public company.
When did AVROBIO go public?
AVROBIO Inc stock began trading on June 21, 2018.